Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (...
Main Authors: | Relinde I. Y. Lieverse, Damiënne Marcus, Alexander M. A. van derWiel, Evert J. Van Limbergen, Jan Theys, Ala Yaromina, Philippe Lambin, Ludwig J. Dubois |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-07-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12705 |
Similar Items
-
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
by: Damiënne Marcus, et al.
Published: (2021-03-01) -
CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B
by: Zhijie Zhang, et al.
Published: (2022-09-01) -
Fibronectin extra domain a limits liver dysfunction and protects mice during acute inflammation
by: Vivek Krishna Pulakazhi Venu, et al.
Published: (2023-06-01) -
Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer
by: Sebastian Sanduleanu, et al.
Published: (2020-05-01) -
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy
by: Veronica Olivo Pimentel, et al.
Published: (2021-03-01)